Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 (RECENTIN) plus FOLFOX versus bevacizumab plus FOLFOX in first-line metastatic colorectal cancer
2005-003440-66Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2006
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of certolizumab pegol in metastatic colon cancer (mCRC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Primary outcome variable. Started Jun 2006; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2005-003440-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003440-66.